Percentage of Spontaneous and F-ara-A–Induced Apoptosis in Antigen-Defined Peripheral Lymphocytes in CLL Patients and Bcl-2 Protein Expression
Patient No. . | Rai Stage . | Spontaneous Apoptosis (%) . | F-ara-A–Induced Apoptosis (%) . | Bcl-2 (ABC) . | ||
---|---|---|---|---|---|---|
CD19+ . | CD3+ . | CD19+ . | CD3+ . | |||
1 | 0 | 6.9 | 9.0 | 85.8 | 61.49 | 48.756 |
2 | 0 | 13.2 | 3.8 | 52.2 | 35.1 | 31.726 |
3 | 0 | 30.6 | 5.8 | 54.5 | 34.3 | 33.150 |
4 | 0 | 43.8 | 1.8 | 81.6 | 35.3 | 28.258 |
5 | 0 | 1.2 | 5.5 | 74.7 | 29.4 | 34.728 |
6 | 0 | 7.5 | 8.6 | 82.8 | 58.9 | 76.320 |
7 | 0 | 1.1 | 0.9 | 41.2 | 53.8 | 41.109 |
8 | 0 | 20.3 | 8.3 | 21.8 | 30.2 | 19.644 |
9 | 0 | 4.7 | 10.1 | 13.1 | 43.0 | ND |
10 | 0 | 25.4 | 8.3 | 60.3 | 17.7 | 28.380 |
11 | 0 | 6.2 | 4.4 | 66.4 | 63.8 | 68.688 |
12 | I | 38.2 | 6.3 | 81.2 | 56.6 | 60.054 |
13 | I | 39.1 | 3.2 | 97.9 | 39.1 | 34.464 |
14 | I | 14.1 | 16.1 | 33.2 | 52.5 | ND |
15 | I | 7.6 | 4.6 | 40.0 | 20.0 | ND |
16 | I | 12.8 | 7.5 | 58.9 | 16.1 | 20.814 |
17 | I | 7.2 | 11.2 | 36.1 | 46.4 | 25.426 |
18 | I | 17.5 | 16.6 | 68.0 | 58.2 | ND |
19 | II | 5.17 | 2.2 | 28.8 | 22.2 | 48.858 |
20 | III | 9.8 | 9.9 | 28.9 | 86.5 | 57.084 |
21 | III | 3.3 | 17.7 | 3.9 | 82.4 | 20.808 |
22 | III | 6.2 | 18.8 | 19.5 | 90.2 | 38.814 |
23 | IV | 10.6 | 7.0 | 16.7 | 67.4 | 100.200 |
24 | IV | 6.5 | 16.2 | 11.9 | 62.2 | ND |
25 | IV | 14.9 | 12.1 | 75.6 | 57.8 | 45.726 |
Patient No. . | Rai Stage . | Spontaneous Apoptosis (%) . | F-ara-A–Induced Apoptosis (%) . | Bcl-2 (ABC) . | ||
---|---|---|---|---|---|---|
CD19+ . | CD3+ . | CD19+ . | CD3+ . | |||
1 | 0 | 6.9 | 9.0 | 85.8 | 61.49 | 48.756 |
2 | 0 | 13.2 | 3.8 | 52.2 | 35.1 | 31.726 |
3 | 0 | 30.6 | 5.8 | 54.5 | 34.3 | 33.150 |
4 | 0 | 43.8 | 1.8 | 81.6 | 35.3 | 28.258 |
5 | 0 | 1.2 | 5.5 | 74.7 | 29.4 | 34.728 |
6 | 0 | 7.5 | 8.6 | 82.8 | 58.9 | 76.320 |
7 | 0 | 1.1 | 0.9 | 41.2 | 53.8 | 41.109 |
8 | 0 | 20.3 | 8.3 | 21.8 | 30.2 | 19.644 |
9 | 0 | 4.7 | 10.1 | 13.1 | 43.0 | ND |
10 | 0 | 25.4 | 8.3 | 60.3 | 17.7 | 28.380 |
11 | 0 | 6.2 | 4.4 | 66.4 | 63.8 | 68.688 |
12 | I | 38.2 | 6.3 | 81.2 | 56.6 | 60.054 |
13 | I | 39.1 | 3.2 | 97.9 | 39.1 | 34.464 |
14 | I | 14.1 | 16.1 | 33.2 | 52.5 | ND |
15 | I | 7.6 | 4.6 | 40.0 | 20.0 | ND |
16 | I | 12.8 | 7.5 | 58.9 | 16.1 | 20.814 |
17 | I | 7.2 | 11.2 | 36.1 | 46.4 | 25.426 |
18 | I | 17.5 | 16.6 | 68.0 | 58.2 | ND |
19 | II | 5.17 | 2.2 | 28.8 | 22.2 | 48.858 |
20 | III | 9.8 | 9.9 | 28.9 | 86.5 | 57.084 |
21 | III | 3.3 | 17.7 | 3.9 | 82.4 | 20.808 |
22 | III | 6.2 | 18.8 | 19.5 | 90.2 | 38.814 |
23 | IV | 10.6 | 7.0 | 16.7 | 67.4 | 100.200 |
24 | IV | 6.5 | 16.2 | 11.9 | 62.2 | ND |
25 | IV | 14.9 | 12.1 | 75.6 | 57.8 | 45.726 |
Peripheral lymphocytes from 25 CLL patients were incubated alone or with F-ara-A, 3 μmol/L for 72 hours. Apoptosis was assessed as the percentage of ISEL-positive cells within the CD3+ and the CD19+ antigen-defined population. Bcl-2 protein expression was quantified in CD5/CD19+ lymphocytes as described in Materials and Methods.
Abbreviation: ND, not determined.